Skip to content
PepFitCoach™
← Peptide library

Metabolic

Semaglutide

Approved medicineHuman clinical evidence

FDA-approved (type 2 diabetes; chronic weight management)

In simple words: A prescription GLP-1 medicine (weekly injection or daily tablet) that lowers appetite and blood sugar.

How it works

It copies the gut hormone GLP-1: boosting insulin when sugar is high, slowing stomach emptying and turning down hunger signals in the brain.

Targets: GLP-1 receptor · Class: GLP-1 receptor agonist

Uses, latest studies & pairings

Typically used for

  • Type 2 diabetes (Ozempic injection, Rybelsus tablet), including kidney protection in diabetic kidney disease.
  • Weight management and lowering heart attack and stroke risk (Wegovy), plus a form of fatty liver disease with scarring (MASH).
  • A once-a-day Wegovy pill was approved for weight management in December 2025.

Commonly paired with

  • Strength training and enough protein (about 1.2–1.6 g per kg of body weight a day, unless your doctor says otherwise) to protect muscle while losing weight.
  • Not combined with other GLP-1 medicines: they work on the same receptors, so stacking adds side effects, not safety.
  • Cagrilintide (an amylin medicine) in the investigational CagriSema combination.
  • Fiber, water and electrolytes to ease stomach side effects.

Latest studies & news

  1. Dec 2025

    Oral Wegovy (25 mg pill) approved in the US for weight management, based on trials averaging about 14% weight loss.

  2. Nov 2025

    EVOKE trials: semaglutide did not slow early Alzheimer's disease.

  3. Aug 2025

    Wegovy received accelerated approval for MASH with moderate-to-advanced liver scarring, after the ESSENCE trial: MASH resolved in about 63% of people versus 34% on placebo.

  4. 2025

    Ozempic approved to lower kidney and heart risk in type 2 diabetes with chronic kidney disease (FLOW trial).

What the research shows

Human clinical evidence

Human
  • STEP 1 (68 weeks, adults with obesity): average weight loss of about 15% with 2.4 mg weekly versus about 2% with placebo (Wilding 2021).
  • Large trials also showed fewer heart attacks, strokes and cardiovascular deaths in people with heart disease and overweight (SELECT trial).
  • Approved as Ozempic and Rybelsus (type 2 diabetes) and Wegovy (weight management, cardiovascular risk reduction and a form of fatty liver disease, MASH).

Animal and lab results suggest what might happen; they don't prove an effect in people.

Safety & what to watch

  • Common: nausea, vomiting, diarrhea, constipation, mostly during dose increases.
  • Boxed warning for thyroid C-cell tumors in rodents; avoid with a personal or family history of MTC or MEN 2.
  • Warnings include pancreatitis, gallbladder disease, worsening diabetic retinopathy with rapid sugar improvement, and a very rare optic-nerve condition (NAION).

Amounts

Prescription only. Your prescriber follows the label's step-up schedule and decides every dose change.

📦 My peptide supply kit

The supplies I use, in one Amazon list. Only use them for medicines your clinician prescribes. Never share or reuse needles, and put used ones in a sharps container.

See my peptide supply kit list on Amazon ↗

Studies & references

  1. Wilding et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021PMID 33567185
  2. FDA prescribing information (DailyMed)
  3. All PubMed studies: semaglutide

Draft profile pending editorial review. Educational only, not medical advice. Never start, stop or change a medicine without your prescriber.